EC Number   |
Application |
Reference |
|---|
   3.4.21.6 | analysis |
development of an assay for the monitoring of anticoagulants inhibiting factor Xa and/or factor IIa. Assay is based on the addition of factor Xa and snake venom RVV-V, i.e. Russell viper venom factor V activator specifically activating factor V and phospholipids to platelet-poor plasma. Assay shows an almost linear dose-response and high sensitivity for unfractionated heparin, low molecular weight heparins, r-hirudin, and argatroban |
695438 |
| 3.4.21.6 | drug development |
factor Xa is a target for development of anticoagulant therapeutics, drug development and clinical trials. overview |
708249 |
| 3.4.21.6 | drug development |
oral factor Xa inhibitors are a promising alternative to current anticoagulants |
708634 |
| 3.4.21.6 | drug development |
structure-based drug design of small molecule factor Xa inhibitors. fXa inhibitors, the so-called xabans, are attractive options that can overcome limitations, e.g. bleeding, of the current oral antithrombotic therapy, he rational design of small-molecule direct fXa inhibitors, overview |
708451 |
| 3.4.21.6 | drug development |
the enzyme is a target for drug development in prevention and treatment of thromboembolic disorders, overview |
707025 |
| 3.4.21.6 | medicine |
enzyme inhibition by anticoagulants are recommended for numerous medical conditions, including the prevention and treatment of venous thromboembolism, stroke prevention in patients with atrial fibrillation, and secondary prevention in acute coronary syndromes |
707903 |
| 3.4.21.6 | medicine |
enzyme is a target for antithrombotic agents |
650933 |
| 3.4.21.6 | medicine |
enzyme is a target for discovery, design of direct inhibitors and development of antithrombotic agents, overview |
650938 |
| 3.4.21.6 | medicine |
FXa is an attractive and potentially specific target for anticoagulant agents |
717968 |
| 3.4.21.6 | medicine |
glycoprotein IIb/IIIa receptor antagonists in combination with heparin might contribute to improved therapy of acute coronary syndromes abd during percutaneous coronary interventions |
653059 |
